

DAFTAR PUSTAKA

1. Suarjana IN. Arthritis Reumatoid. Dalam Buku ajar ilmu Penyakit dalam Edisi enam. Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Interna Publishing; 2014:3130–50.
2. Vidal B, Cascao R, Mikko A, Lopes I, Saarakkala S, Zioupsos P et al. Early arthritis induces disturbances at bone nanostructural level reflected in decreased tissue hardness in an animal model of arthritis. *Plos One*. 2018 Jan; 13(1): 1–16.
3. Karsdal MA, Woodworth T, Henriksen K, Maksymowch W, Genant H, Vergnaud P et al. Biochemical markers of ongoing joint damage in arthritis reumatoid - current and future applications, limitations and opportunities. *Arthritis Res ther*. 2011 Apr; 13(2): 1–20.
4. Próchnicka RK, Gorycka PA, Mariczak M, Glemza FA, Wojciechowaka M, Wojdaslewicz P et al. Biologics Treatment Limits Disease Activity and Bone Metabolism in Patients with Arthritis reumatoid. *Rheumatology (Sunnyvale)* 2016; 6(4): 1–8 .
5. Denaria D, Constant E, Thomas T, Marotte H. Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Arthritis reumatoid Patients? *Hindawi Publishing Corporation Mediators of Inflammation*. 2014 March: 1–7.
6. Guo Q, wang Y, Xu D, Nossent J, Avlos NJ, Xu J. Arthritis reumatoid: pathological mechanisms and modern pharmacologic therapies. *Bone Res*. 2018 April; 6:15: 1–14.
7. Soeroso J, Judajana FM, Kalim H. HLA-DRB1 and DQB1 alleles associated with Arthritis reumatoid in Java and Bali Islands, Indonesia. *Indonesian J Clin Pathol Lab Med*. 2012; 18(3):150–7.
8. Onna MV, Boonen A. The challenging interplay between arthritis reumatoid, ageing and comorbidities. *BMC Musculoskeletal Disorders*. 2016; 17:184.
9. Magyari L, Varszegi D, Kovesdi E, Sarlos P, Farago B, Javorhazy A et al. Interleukins and interleukin receptors in arthritis reumatoid: Research, diagnostics and clinical implications. *World J Orthop*. 2014; 5(4): 516–36
10. Firestein G, McInnes B. Immunopathogenesis of arthritis reumatoid. *Immunity*. 2017; 46(2): 1–14.
11. Ardle AM, Flatley B, Pennington SR, FitzGerald O. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. *Arthritis Res Ther*. 2015 Jun; 17:141: 1–12.

12. Achour WB, Bouaziz M, Mechri M, Zouari B, Bahlous A, Abdelmoula L et al. A cross sectional study of bone and cartilage biomarkers: correlation with structural damage in arthritis reumatoid. *Libyan J Med*. 2018 Dec; 13(1): 1–7
13. Vidal B, Cascao R, Vale AC, Cavaleiro I, Vaz MF, Brito JA et al. Arthritis Induces Early Bone High Turnover, Structural Degradation and Mechanical weakness. *Plos one*. 2015 Jan; 10(9): 1–10.
14. Brzustewicz E, Bryl E. The role of cytokines in the pathogenesis of arthritis reumatoid – Practical and potential application of cytokines as biomarkers and targets of personalized therapy. *elsevier*. 2015 Dec; 76(2): 527–36.
15. Pratiwi RD, Sahid MN. Synovium Targeting Delivery of TNF α Blocker for Arthritis reumatoid Therapy. *Journal of Applied Pharmaceutical Science*. 2018 Oct; 8(10): 165–71.
16. Mobini M, Kashi Z, Ghobadifar A. Prevalence and associated factors of osteoporosis in female patients with arthritis reumatoid. *Caspian J Intern Med*. 2012; 3(3): 447–50.
17. Akil N, Isbagio H, Sumariyono. Correlation of serum level of interleukin-6 and disease activity with bone-resorption activity in premenopausal arthritis reumatoid patients. *Indonesian Journal of Rheumatology*. 2013; 4: 20–4.
18. Chung L, Dinakarbandian D, Yoshida N, Janelle L, Fields GB, Visse R, et al. Collgenase unwinds triple-helical collagen prior to peptide bond hydrolysis. *The EMMBO journal*. 2004; 23: 3020–30
19. Ricard-Blum S. *The Collagen Family*. *Cold Spring Harb Perspect Biol* 2011;. 3 (1): 1-19.
20. Garnero P, Jouvenne P, Buchs N, Delmas PD, Miossec P. Uncoupling of bonemetabolism in arthritis reumatoid patients with or without joint destruction: assessment with serum type I collagenbreak down products. 2012; 24(4): 381–5.
21. Syversen SW, Haavardsholm EA, Boyesen P, Goll GL, Okkenhaug C, Gaarder PI, et al. Biomarkers in early arthritis reumatoid: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. *Ann Rheum Dis*. 2010;69:845–50.
22. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. *Immunol Rev*. 2005; 208: 30–49.

23. Meyer PW, Hodkinson B, Ally M, Musenge E, Wade AA, Fickl H et al. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with arthritis reumatoid, *Mediators Inflamm*. 2010: 1–10.
24. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. *Rheumatology*. 2012 ; 51 : :v3–v11.
25. Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI. Smoking and Rheumatoid Arthritis. *Int. J. Mol. Sci*. 2014 ; 15 : 22279–95.
26. Firestein GS. The disease formerly known as arthritis reumatoid. *Arthritis Res Ther*. 2014; 16(3):114.
27. Liu X, Zeng B, Zhang J, Li W, Mou F, wang H et al. Role of the Gut Microbiome in Modulating Arthritis Progression in Mice. *Sci Rep*. 2016; 6: 1–11.
28. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. *Nat Rev Drug Discov*. 2012; 11(10):763–76.
29. Wegner N, wait R, Sroka A, Eick S, Nguyen KA, Lundberg K et al.. Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and α -enolase: implications for autoimmunity in arthritis reumatoid. *Arthritis Rheum*. 2010; 62(9):2662–72.
30. de Aquino SG, Abdollahi r S, Koenders MI, Van DL, Pruijn GJ, Marijnissen RJ, et al. Periodontal pathogens directly promote autoimmune experimental arthritis by inducing a TLR2- and IL1-driven Th17 response. *J Immunol*. 2014 May; 192(9) :4103–11.
31. Darrah E, Andrade F. Rheumatoid arthritis and citrullination. *Medical physiology and rheumatic diseases*. 2017 ; 29 : 1–7,
32. Kay J, Calebrese L. The role of interleukin-1 in the pathogenesis of arthritis reumatoid. *Rheumatology*. 2004 Jun; 43(3): 1–9.
33. MClInnes IB, Scheet G. The pathogenesis of rheumathoid arthritis. *N Engl J Med* 2011;365:2205–19.
34. Jung SM, Kim KW, Yang CW, Park SH, Ju JH. Cytokine-Mediated Bone Destruction in Arthritis reumatoid. *Journal of Immunology Research Volume*. 2014: 1-15.
35. Hung SJ, Kwon YJ, Park MC, Park YB, Lee SK. The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Arthritis reumatoid Patients. *Yonsei Med J*. 2011; 52(1): 113–20.

36. Wu J, Qu Y, Deng JX, Liang WY, Jiang ZL, Lai R et al. Resveratrol inhibition of TNF- α and IL-1 for treatment of arthritis reumatoid: from *In-Silico* to *In-vitro* elucidation. *Int J Clin Exp Med*. 2016; 9(2):745–52.
37. Nalbant S, Birlik AM. Cytokines in Arthritis reumatoid (RA). *InTech*. 2017: 55–63.
38. Farrugia M, Baron B. The role of TNF- α in arthritis reumatoid: a focus on regulatory T cells. *Journal of Clinical and Translational Research*. 2016; 2(3): 84–90
39. Lacativa PG, Farias ML. Osteoporosis and inflammation. *Arq Bras Endocrinol Metabol*. 2010 Mar; 54(2): 123–32.
40. Zerbini CAF, Clark P, Sanchez LM, Pereira RM, Messina OD, Una Cr et al. Biologic therapies and bone loss in arthritis reumatoid. *Osteoporos Int*. 2017 Feb; 28(2): 429–46.
41. Manara M, Sinigaglia L. Bone and TNF in arthritis reumatoid: clinical implications. *RMD Open*. 2015;1: 1–6.
42. Tetta C, Camussi G, Modena V, Vittorio CD, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe arthritis reumatoid. *Annals of the Rheumatic Diseases*. 1990; 49: 665–7
43. Wei ST, Sun YH, Zong SH, Xiang YB. Serum Levels of IL-6 and TNF- α May Correlate with Activity and Severity of Arthritis reumatoid. *Med Sci Monit*. 2015 Dec; 21: 4030–38
44. Takahata M, Jason R, Maher, Subhash C, Juneja, Inzana J et al. Mechanisms of bone fragility in a glucocorticoid-treated mouse model of arthritis reumatoid – implications for insufficiency fracture risk. *Arthritis Rheum*. 2012; 64(11): 3649–59
45. Altomonte I, Zoli A, Mirone L, Scolieri P, Magaro M. Serum levels of interleukin-1 β , tumour necrosis factor- α and interleukin-2 in arthritis reumatoid. Correlation with disease activity. *Clin Rheumatol*. 1992; 11: 202–5
46. Liu Y, Cui Y, Chen Y, Gao X, Su C, Cui L. Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats. *Clinical Interventions in Aging*. 2015 Aug; 10: 1245–53.
47. Schett G. Bone erosion in arthritis reumatoid: mechanisms, diagnosis and treatment. *Nat Rev Rheumatol*. 2012; 8(11): 656–64
48. Matzell MM, Gallant MA, Condon KW, Walsh NC, Manning CA, Stein GS et al. Resolution of Inflammation Induces Osteoblast Function and Regulates the Wnt Signaling Pathway. *Arthritis Rheum*. 2012; 64(5): 1540–50.

49. Arnett TR. Bone Structure and bone remodeling. Researchgate. 2014: 1-10.
50. Wheeler G, Elshahaly M, Tuck SP, Datta HK, Van laar JM. The clinical utility of bone marker measurements in osteoporosis. *Journal of Translational Medicine*. 2013 Aug; 11(1): 1–14
51. Forsblad H, Christgau S, Mattsson LA, Ohlsson C, Nordborg E, Carlsten H. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in arthritis reumatoid: a randomized controlled trial. *Arthritis Res Ther*. 2004; 6(5) : 457–68.
52. Warriner A, Saag KG. Prevention and Treatment of Bone Changes Associated with Exposure to Glucocorticoids. *Curr Osteoporos Rep*. 2013 ; 11(4): 341–47
53. Panagiotis K, Panagopoulou, Lambrou GL. Bone erosions in arthritis reumatoid: recent developments in pathogenesis and therapeutic Implications. *J Musculoskelet Neuronal Interact* 2018; 18(3): 304–19
54. Lems WF. Glucocorticoids: bad or safe for the bones?. *RMD Open*. 2015; 1(1): 1–4.
55. Briot K, Roux C. Glucocorticoid-induced osteoporosis. *RMD Open*. 2015 ; 1 : 1–8
56. Rossini M, Fassio A, Idolazzi L, Viapiana O, Fracassi E, Adami G, Povino RM et al. Pathogenesis of Bone Erosions in Arthritis reumatoid: Not Only Inflammation. *J Rheum Dis Treat*. 2015; 1(2) :1–5
57. Svensson B, Boonen A, Albertsson K, Van der HD, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active arthritis reumatoid reduces joint destruction and increases the remission rate: a two-year randomized trial. *Arthritis Rheum* 2005;52: 3360–70.
58. Geusens P, Lems WF. Osteoimmunology and osteoporosis. *Arthritis Research & Therapy*. 2011; 13:242: 1–16
59. Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. *Clinical Chemistry*. 2017; 63:2: 464–74
60. Denarle D, Constant E, Thomas T, Marotte H. Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Arthritis reumatoid Patients? Hindawi Publishing Corporation *Mediators of Inflammation*. 2014: 1–7.
61. Carrasco R, Barton A. Biomarkers of outcome in arthritis reumatoid. *Rheumatology Reports*. 2010; 2(1): 26–38.

62. Matthew B. Greenblatt¹, Joy N. Tsai², and Marc N. Wein². Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. *Clin Chem*. 2017; 63(2): 464–74.
63. Bhattoa H. Laboratory aspects and clinical utility of bone turnover markers. *eJIFCC*. 2018; 29(2): 117–28.
64. Jansen Lm, Bruinsma IV, Lems WF, Schaardenburg VD, Stadt, Koning MD, Dijkmans. Serological bone markers and joint damage in early polyarthritis. *J Rheumatol*. 2004; 31; 1491–6.
65. Wislowska M, Jakubicz D, Stdziej K, Cicha M. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in arthritis reumatoid. *Rheumatol Int*. 2009; 29: 1403–9
66. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and arthritis reumatoid severity. *Annals of the Rheumatic Diseases*. 1997; 56: 463–69.
67. Rydell E , Forslind K, Nilsson JA, Jacobsson LT, Turesson C. Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early arthritis reumatoid. *Arthritis Research & Therapy*. 2018. 20(1): 82: 1–11.
68. Fransen J, Riel PL, The Disease Activity Score and the EULAR response criteria. *Clin Exp Rheumatol*. 2005; 23(39): S93–9.
69. Nielung L, Christensen R, Samsøe BD, Bliddal H, Holm CC, Ellegaard K et al. Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Arthritis reumatoid. Hindawi Publishing Corporation *Arthritis*. 2015; 1–6.
70. Salaffi F, Ciapetti A. Clinical disease activity assessments in rheumatoid arthritis. *Int. J. Clin. Rheumatol*. 2013; 8(3): 347–60.
71. Soeroso J, Judajana FM. Hubungan antara umur, umur mulai sakit, lama sakit dengan LED, CRP, DAS28-LED di arthritis reumatoid. *Indonesian J Clin Pathol Lab Med*. 2014; 20(2): 85-92.
72. Voulgar PV, Papadopoulos LA, Alamanos Y, Katsaraki A, Drosos AA. Early rheumatoid arthritis: Does gender influence disease expression?. *Clinical and Experimental Rheumatology*. 2004; 22: 165–70.

73. Vollenhove RF. Sex differences in rheumatoid arthritis: more than meets the eye. *BMC Medicine*. 2009 March; 7:12: 1–4.
74. Orbai AM Bingham CO. Patient reported outcomes in rheumatoid arthritis. 2017; 17(4): 1–19.
75. Engelmann R, Wang N, Kneitz C, Hilke BM. Bone resorption correlates with the frequency of CD5+ B cells in the blood of patients with rheumatoid arthritis. *Rheumatology*. 2015; 54: 545–53.
76. Beyazal MS, Devrimsel G, Cüre3 MC, Türkyılmaz AK, Çapkın5 E, Karkucak6 M. Serum Levels of IL-17, IL-6, TNF- α and Disease Activity in Patients with Rheumatoid Arthritis. *Akt Rheumatol*. 2017; 42: 323–28.
77. Ruliani H, Kalim H, Suryana BP, Handono K. Korelasi Kadar Vitamin D, dengan TNF- dan Manifestasi Klinis pada Pasien Artritis Rematoid The Correlation of Vitamin D, TNF- α , and Clinical Manifestation in Rheumatoid Arthritis Patients. *Jurnal Kedokteran Brawijaya*. 2014 Feb; 28(1): 30–4.
78. Mudjaddid E, Puspitasari M, Setyohadi M, Dewiasty E. Hubungan derajat aktivitas penyakit dengan depresi pada pasien arthritis rheumatoid. 2017; JPDI: 194–8.
79. Handono K, suryana BP, Sulistyorini. Korelasi Kadar CRP, Tnf- α Dan Bone Mineral Density Dengan Carboxyterminal Crosslinked Telopeptide Type I Of Collagen Di Penderita Artritis Reumatoid. *IJCP & ML*. 2012; 18 (2): 77–82.
80. Hlaing TT, Compston JE. Biochemical markers of bone turnover – uses and limitations. *Annals of Clinical Biochemistry* 2014; Vol. 51(2): 189–202
81. Harth M, Pope J. The Measure of Our Measures. *Rheumatology*. 2004 ; 43 (12) : 1465–67.
82. Ma J, Zhang Y, Gong 1, Zhu Y, Ming L, Zhao J. Correlation between plasma levels of D-dimer and IL-1, IL-6, and TNF- α in patients with rheumatoid arthritis. *Int J Clin Exp Med*. 2018;11(9): 9865–71.
83. Jancic I, Bukilica SB, Zivojinovic S, Damjanov N, Spasovski V, Kotur N *et al*. Influence Of Promoter Polymorphisms Of The TNF- α (-308G/A) and IL-6 (-174G/C) Genes On Therapeutic Response to Etanercept In Rheumatoid Arthritis. *J Med Biochem*. 2015; 34 (4) : 414–21.

84. Salman AN, Kudair AM. Evaluating Levels Of Interleukin-1 β And Interleukin- 17 In Rhumatoid Arthritis Patients In Thi-Qar Province. World Journal of Pharmaceutical Research. 2015; 4(10): 281–8
85. Shafiaa S, Shaha ZA, Sofib FA. TNF-A, IL-1 β and IL-6 Cytokine Gene Expression in Synovial Fluid of Rheumatoid Arthritis and Osteoarthritis Patients and Their Relationship with Gene Polymorphisms. Rheumatology (Sunnyvale). 2016; 6(1): 1–6

